Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus FLOXIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus FLOXIN IN DEXTROSE 5.
CIPROFLOXACIN HYDROCHLORIDE vs FLOXIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
500-750 mg orally every 12 hours; 400 mg intravenously every 8-12 hours.
400 mg intravenously every 12 hours.
None Documented
None Documented
Terminal half-life 4 hours (3-5 h) in normal renal function; prolonged to 5-10 h in mild-to-moderate renal impairment and >10 h in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Renal: 50-70% unchanged drug; biliary/fecal: 15-25% (partly as metabolites).
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic